Sep. 11 at 8:46 PM
$CNTB SO:
Monday, September 14: The H.C. Wainwright 28th Annual Global Investment Conference: Sep: 14–16
Tuesday, September 15, 9:30 a.m. Boston time: Barry Quart speaks at the COPD Drug Development Summit in Boston.
Tuesday, September 15, 11:30 a.m. ET: Connect Biopharma is also scheduled for its H.C. Wainwright fireside chat.
Not the interesting part: What exactly is Barry speaking about?
“Repositioning Rapid Acting IL-4Rα Biologics for Acute Exacerbations in Asthma & COPD: A Dual-Phase Approach to Rapid Lung Function Recovery & Inflammatory Control.”
Barry will argue three things.
* First, that rapidly acting IL-4Rα antibodies can potentially be used during an acute asthma or COPD exacerbation
* he will discuss recovery of airway function within “minutes to hours,” leading to clinically meaningful FEV1 improvement.
* “dual-phase” treatment concept: acute dose → rapid improvement in lung function → continued IL-4/IL-13 inflammatory suppression → sustained control after the exacerbation.
